Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection

The authors aimed to evaluate the cost-effectiveness of commercial, FDA-approved microbiota therapeutics compared to traditional fecal microbiota transplantation (FMT) via colonoscopy for managing recurrent Clostridioides difficile infection (rCDI). Their findings indicate that traditional FMT is the most cost-effective strategy, with an incremental cost-effectiveness ratio of $44,158, while commercial microbiota therapeutics are not cost-effective when donor-derived FMT is available. Overall, the study concludes that colonoscopic FMT remains the optimal approach for preventing subsequent rCDI episodes.